- Tipiracil
-
- $30.00
-
2026-05-11
- CAS:183204-74-2
- Purity: 99.81%
- Supply Ability: 10g
|
| | Tipiracil Basic information |
| Product Name: | Tipiracil | | Synonyms: | 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione,;5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione;MA 1 (pharmaceutical);TPI (thymidine phosphorylase inhibitor);2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-;2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidi...;Tipiracil D4Q: What is
Tipiracil D4 Q: What is the CAS Number of
Tipiracil D4;Tipiracil | | CAS: | 183204-74-2 | | MF: | C9H11ClN4O2 | | MW: | 242.66 | | EINECS: | | | Product Categories: | | | Mol File: | 183204-74-2.mol |  |
| | Tipiracil Chemical Properties |
| density | 1.71±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Water: 1 mg/mL (4.12 mM); DMSO: < 1 mg/mL (insoluble or slightly soluble) | | pka | 7.06±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Tipiracil Usage And Synthesis |
| Uses | Tipiracil-13C, 15N2 is carbon-13 and nitrogen-15 labeled Tipiracil,an inhibitor of human thymidine phosphorylase (TP).Thymidine phosphorylase is an enzyme that converts thymidine to thymine and is a platelet-derived endothelial cell growth factor. | | Definition | ChEBI: Tipiracil is a member of the class of pyrimidones that is uracil substituted by chloro and (2-iminopyrrolidin-1-yl)methyl groups at positions 5 and 6 respectively. Used (as the hydrochloride salt) in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. It has a role as an antineoplastic agent and an EC 2.4.2.4 (thymidine phosphorylase) inhibitor. It is a pyrimidone, an organochlorine compound, a carboxamidine and a member of pyrrolidines. It is functionally related to a uracil. It is a conjugate base of a tipiracil(1+). | | Mode of action | Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF or anti-EGFR therapy. |
| | Tipiracil Preparation Products And Raw materials |
|